Coeptis Therapeutics (NASDAQ:ZSQR) Sees Large Volume Increase – Here’s What Happened

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) saw unusually-strong trading volume on Wednesday . Approximately 214,714 shares were traded during mid-day trading, an increase of 156% from the previous session’s volume of 84,030 shares.The stock last traded at $9.87 and had previously closed at $9.47.

Coeptis Therapeutics Stock Performance

The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. The firm has a market cap of $508.64 million, a PE ratio of -3.92 and a beta of -0.09. The firm has a 50-day moving average price of $12.10 and a two-hundred day moving average price of $13.39.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ZSQR. Steward Partners Investment Advisory LLC lifted its position in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares in the last quarter. Yorkville Advisors Global LP purchased a new position in shares of Coeptis Therapeutics during the 3rd quarter worth $140,000. Marshall Wace LLP acquired a new position in shares of Coeptis Therapeutics during the 4th quarter valued at about $259,000. State Street Corp grew its holdings in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after purchasing an additional 6,962 shares during the period. Finally, Geode Capital Management LLC increased its position in Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares during the last quarter. 13.88% of the stock is owned by hedge funds and other institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.